Panel Overview
Behind today’s rapidly expanding clinical pipelines, CMC has emerged as one of the most critical factors determining whether an ADC can successfully reach the market. Recent FDA setbacks involving Chinese ADC assets have drawn significant industry attention, highlighting that CMC is no longer simply a back-office function, but a strategic priority that can influence company valuations, BD deal terms and long-term global competitiveness.
Against this backdrop, China BioPioneers International Edition returns with its second episode: “The ADC Commercialization Era: From CMC Excellence to Building Global Competitiveness.” Co-hosted by Healthcare Executive, Weijieyao, Asymchem and AsymBio, the panel will explore how CMC and manufacturing strategy influence an ADC’s path to commercial supply and global markets.
What We Will Cover
CMC – The Invisible Arbiter of ADC Commercialization
The Crossroads of Manufacturing Strategy – In-House, CDMO, or Hybrid?
Global CMC Compliance – Navigating Regulatory Expectations Across Markets
Supply Chain Resilience – From Cost Efficiency to Strategic Security
Looking Ahead – How CMC Will Shape the Next Generation of ADC Leaders
